Terapevticheskii arkhivTerapevticheskii arkhivТерапевтический архив0040-36602309-5342LLC Obyedinennaya Redaktsiya3285210.26442/00403660.2018.12.000001Editorial articleПередовая статьяReview ArticleAdherence to therapy of patients with inflammatory bowel diseasesПриверженность терапии больных с воспалительными заболеваниями кишечникаParfenovA IПарфеновАсфольд Иванович

д.м.н., проф., зав. отд. патологии кишечника

asfold@mail.ruKagramanovaA VКаграмановаАнна Валерьевна

к.м.н., с.н.с. отд-ния воспалительных заболеваний кишечника

BabayanA FБабаянАнаит Фахрадовна

врач-гастроэнтеролог отд-ния воспалительных заболеваний кишечника

KnyazevO VКнязевОлег Владимирович

д.м.н., зав. отд-нием воспалительных заболеваний кишечника

A.S. Loginov Moscow Clinical Scientific Center of the Department of Health of MoscowГБУЗ «Московский клинический научно-практический центр им. А.С. Логинова» Департамента здравоохранения г. Москвы151220189012VOL 90, NO12 (2018)ТОМ 90, №12 (2018)41111042020Copyright ©; 2018, Consilium MedicumCopyright ©; 2018, ООО "Консилиум Медикум"2018Consilium MedicumООО "Консилиум Медикум"https://creativecommons.org/licenses/by-nc-sa/4.0https://ter-arkhiv.ru/0040-3660/article/view/32852

Inflammatory bowel diseases are autoimmune systemic forms of pathology. The concept of continuous life-long drug intake is a cornerstone in their therapy. The review presents the factors that reduce patients adherence to treatment and ways to improve it. They include informing the patient about the disease and treatment, selection of individual therapy regimen, consolidation of achievements, provision of social support and interaction with other specialists.

Воспалительные заболевания кишечника относятся к аутоиммунным системным формам патологии. Концепция постоянного пожизненного приема лекарственных препаратов является краеугольным камнем в их терапии. В обзоре представлены факторы, снижающие приверженность больных лечению и пути ее повышения. Они включают информирование пациента о заболевании и лечении, подбор индивидуального режима терапии, закрепление достигнутого, обеспечение социальной поддержки и взаимодействие с другими специалистами.

Crohn's diseaseinflammatory bowel diseasemethods of measuring adherencequestionnairesadherence to therapycomplianceulcerative colitisscalesболезнь Кронавоспалительные заболевания кишечникаметоды измерения приверженностиопросникиприверженность терапиикомплаенсязвенный колитшкалыChan W, Chen A, Tiao D, Selinger C, Leong R. Medication adherence in inflammatory bowel disease. Intest Res. 2017 Oct;15(4):434-45. doi: 10.5217/ir.2017.15.4.434. Epub 2017 Oct 23. Review.Cramer J.A, Roy A, Burrell A, Fairchild C.J, Fuldeore M.J, Ollendorf D.A, Wong P.K. Medication compliance and persistence: terminology and definitions. Value Health. 2008;11(1):44-7.Sackett D.L, Haynes R.B. Compliance with therapeutic regimens. Baltimore: The Johns Hopkins University Press; 1976.Vrijens B, De Geest S, Hughes D.A, et al. A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol. 2012;73:691-705. doi: 10.1111/j.1365-2125.2012.04167.xJackson C.A, Clatworthy J, Robinson A, Horne R. Factors associated with non - adherence to oral medication for inflammatory bowel disease: a systematic review. Am J Gastroenterol. 2010;105:525-39. doi: 10.1038/ajg.2009.685Kawakami A, Tanaka M, Nishigaki M, et al. Relationship between non - adherence to aminosalicylate medication and the risk of clinical relapse among Japanese patients with ulcerative colitis in clinical remission: a prospective cohort study. J Gastroenterol. 2013;48:1006-15. doi: 10.1007/s00535-012-0721-xKim S.B, Kim K.O, Jang B.I, et al. Patients’ beliefs and attitudes about their treatment for inflammatory bowel disease in Korea. J Gastroenterol Hepatol. 2016;31:575-80. doi: 10.1111/jgh.13155Spekhorst L.M, Hummel T.Z, Benninga M.A, van Rheenen P.F, Kindermann A. Adherence to oral maintenance treatment in adolescents with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2016;62:264-70. doi: 10.1097/MPG.0000000000000924Jeganathan J, Lee C.H, Rahme A, et al. Medication adherence in transitional inflammatory bowel disease patients: a multicenter pilot study. J Gastroenterol Hepatol. 2014;29:111.Selinger C, Robinson A, Leong R. Non - adherence to inflammatory bowel disease maintenance medication: extent and predictors. J Gastroenterol Hepatol. 2011;26:116.Lopez A, Billioud V, Peyrin-Biroulet C, Peyrin-Biroulet L. Adherence to anti-TNF therapy in inflammatory bowel diseases: a systematic review. Inflamm Bowel Dis. 2013;19:1528-33. doi: 10.1097/MIB.0b013e31828132cbKane S, Huo D, Aikens J, Hanauer S. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med. 2003;114:39-43.Khan N, Abbas A.M, Bazzano L.A, Koleva Y.N, Krousel-Wood M. Long - term oral mesalazine adherence and the risk of disease flare in ulcerative colitis: nationwide 10-year retrospective cohort from the veterans affairs healthcare system. Aliment Pharmacol Ther. 2012;36:755-64. doi: 10.1111/apt.12013Van der Have M, Oldenburg B, Kaptein A.A, et al. Non - adherence to anti-TNF therapy is associated with illness perceptions and clinical outcomes in outpatients with inflammatory bowel disease: results from a prospective multicentre study. J Crohns Colitis. 2016;10:549-55. doi: 10.1093/ecco-jcc/jjw002Kane S, Shaya F. Medication non - adherence is associated with increased medical health care costs. Dig Dis Sci. 2008;53:1020-4. doi: 10.1007/s10620-007-9968-0Hommel K.A, Davis C.M, Baldassano R.N. Medication adherence and quality of life in pediatric inflammatory bowel disease. J Pediatr Psychol. 2008;33:867-74. doi: 10.1093/jpepsy/jsn022Horváth G, Farkas K, Hollósi R, et al. Is there any association between impaired health - related quality of life and non - adherence to medical therapy in inflammatory bowel disease? Scand J Gastroenterol. 2012;47:1298-303. doi: 10.3109/00365521.2012.703233Perry J, Chen A, Kariyawasam V, Choong C, Teh W.L, Mitrev N, Kohler F, Leong R.W.L. Medication non - adherence in inflammatory bowel diseases is associated with disability. Intest Res. 2018 Oct;16(4):571-8. doi: 10.5217/ir.2018.00033Robinson A, Hankins M, Wiseman G, Jones M. Maintaining stable symptom control in inflammatory bowel disease: a retrospective analysis of adherence, medication switches and the risk of relapse. Aliment Pharmacol Ther. 2013;38:531-8. doi: 10.1111/apt.12396Cramer J.A, Scheyer R.D, Mattson R.H. Compliance declines between clinic visits. Arch Intern Med. 1990;150:1509-10.Fong S, Ward M.G, Nasr I, et al. PWE-111 higher red blood cell methotrexate polyglutamates correlate with increased disease activity, and are useful in assessing adherence. Gut. 2014;63(Suppl 1):A173.Gifford A.E, Berg A.H, Lahiff C, Cheifetz A.S, Horowitz G, Moss A.C. A random urine test can identify patients at risk of mesalamine non - adherence: a prospective study. Am J Gastroenterol. 2013;108:249-55. doi: 10.1038/ajg.2012.419Andrade S.E, Kahler K.H, Frech F, Chan K.A. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf. 2006;15:565-74. doi: 10.1002/pds.1230Nguyen T.M, La Caze A, Cottrell N. What are validated selfreport adherence scales really measuring? A systematic review. Br J Clin Pharmacol. 2014;77:427-45. doi: 10.1111/bcp.12194Morisky D.E, Di Matteo M.R. Improving the measurement of selfreported medication nonadherence: final response. J Clin Epidemiol. 2011;64:262-3.Trindade A.J, Ehrlich A, Kornbluth A, Ullman T.A. Are your patients taking their medicine? Validation of a new adherence scale in patients with inflammatory bowel disease and comparison with physician perception of adherence. Inflamm Bowel Dis. 2011;17:599-604. doi: 10.1002/ibd.21310Kane S, Becker B, Harmsen W.S, Kurian A, Morisky D.E, Zinsmeister A.R. Use of a screening tool to determine nonadherent behavior in inflammatory bowel disease. Am J Gastroenterol. 2012;107:154-60. doi: 10.1038/ajg.2011.317Selinger C.P, Eaden J, Jones D.B, et al. Modifiable factors associated with nonadherence to maintenance medication for inflammatory bowel disease. Inflamm Bowel Dis. 2013;19:2199-206. doi: 10.1097/MIB.0b013e31829ed8a6Moss A.C, Lillis Y, Edwards George J.B, et al. Attitudes to mesalamine questionnaire: a novel tool to predict mesalamine nonadherence in patients with IBD. Am J Gastroenterol. 2014;109:1850-5. doi: 10.1038/ajg.2014.158Waters B.M, Jensen L, Fedorak R.N. Effects of formal education for patients with inflammatory bowel disease: a randomized controlled trial. Can J Gastroenterol. 2005;19:235-44.Tiao D.K, Jeganathan J, Chen A., et al. Impact of targeted pharmacist counselling intervention on IBD medication adherence. J Gastroenterol Hepatol. 2014;29:106.Kripalani S, Yao X, Haynes R.B. Interventions to enhance medication adherence in chronic medical conditions: a systematic review. Arch Intern Med. 2007;167:540-50. doi: 10.1001/archinte.167.6.540Kane S, Huo D, Magnanti K. A pilot feasibility study of once daily versus conventional dosing mesalamine for maintenance of ulcerative colitis. Clin Gastroenterol Hepatol. 2003;1:170-3.Dignass A.U, Bokemeyer B, Adamek H, et al. Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis. Clin Gastroenterol Hepatol. 2009;7:762-9.Suzuki Y, Iida M, Ito H, et al. 2.4 g Mesalamine (Asacol 400 mg tablet) once daily is as effective as three times daily in maintenance of remission in ulcerative colitis: a randomized, noninferiority, multi - center trial. Inflamm Bowel Dis. 2017;23:822-32. doi: 10.1097/MIB.0000000000001065Fenerty S.D, West C, Davis S.A, Kaplan S.G, Feldman S.R. The effect of reminder systems on patients’ adherence to treatment. Patient Prefer Adherence. 2012;6:127-35. doi: 10.2147/PPA.S26314Greenley R.N, Gumidyala A.P, Nguyen E, et al. Can you teach a teen new tricks? Problem solving skills training improves oral medication adherence in pediatric patients with inflammatory bowel disease participating in a randomized trial. Inflamm Bowel Dis. 2015;21:2649-57. doi: 10.1097/MIB.0000000000000530Cook P.F, Emiliozzi S, El-Hajj D, Mc Cabe M.M. Telephone nurse counseling for medication adherence in ulcerative colitis: a preliminary study. Patient Educ Couns. 2010;81:182-6. doi: 10.1016/j.pec.2009.12.010Elkjaer M, Shuhaibar M, Burisch J, et al. E-health empowers patients with ulcerative colitis: a randomised controlled trial of the web - guided ‘Constant - care’ approach. Gut. 2010;59:1652-61. doi: 10.1136/gut.2010.220160Moshkovska T, Stone M.A, Smith R.M, Bankart J, Baker R, Mayberry J.F. Impact of a tailored patient preference intervention in adherence to 5-aminosalicylic acid medication in ulcerative colitis: results from an exploratory randomized controlled trial. Inflamm Bowel Dis. 2011;17:1874-81. doi: 10.1002/ibd.21570Hommel K.A, Herzer M, Ingerski L.M, Hente E, Denson L.A. Individually tailored treatment of medication nonadherence. J Pediatr Gastroenterol Nutr. 2011;53:435-9. doi: 10.1097/MPG.0b013e3182203a91Hommel K.A, Hente E.A, Odell S, et al. Evaluation of a groupbased behavioral intervention to promote adherence in adolescents with inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2012;24:64-9. doi: 10.1097/MEG.0b013e32834d09f1Aguas Peris M, Del Hoyo J, Bebia P, et al. Telemedicine in inflammatory bowel disease: opportunities and approaches. Inflamm Bowel Dis. 2015;21:392-9. doi: 10.1097/MIB.0000000000000241Pedersen N, Thielsen P, Martinsen L, et al. eHealth: individualization of mesalazine treatment through a self - managed webbased solution in mild - to - moderate ulcerative colitis. Inflamm Bowel Dis. 2014;20:2276-85. doi: 10.1097/MIB.0000000000000199Cross R.K, Cheevers N, Rustgi A, Langenberg P, Finkelstein J. Randomized, controlled trial of home telemanagement in patients with ulcerative colitis (UC HAT). Inflamm Bowel Dis. 2012;18:1018-25. doi: 10.1002/ibd.21795Hommel K.A, Hente E, Herzer M, Ingerski L.M, Denson L.A. Telehealth behavioral treatment for medication nonadherence: a pilot and feasibility study. Eur J Gastroenterol Hepatol. 2013;25:469-73. doi: 10.1097/MEG.0b013e32835c2a1b